TTI-109

May 8, 2026: Tvardi Therapeutics, Inc. (NASDAQ: TVRD) reported Q1 2026 financial results and outlined upcoming clinical catalysts for its STAT3 inhibitor programs.

TTI-109 (next-generation STAT3 inhibitor; Phase 1 healthy volunteer study): The study is ongoing, with topline data anticipated in June 2026. Tvardi expects these results to inform and accompany an announced clinical development strategy.

TTI-101:

• Hepatocellular carcinoma (HCC) – REVERT LIVER CANCER (Phase 1b/2): Topline results are on track for 2H 2026.
• Idiopathic pulmonary fibrosis (IPF) – REVERT IPF (Phase 2; additional analyses): The company cited Phase 2 findings showing TTI-101 was associated with a 9.4% baseline-weighted reduction in fibrosis score versus 2.4% with placebo, and a 4.5-fold greater decline in IL-6 versus placebo.

Financials/cash: Cash, cash equivalents, and short-term investments were $25.0 million as of March 31, 2026, and the company expects its cash runway to fund operations through clinical readouts and into Q4 2026. Key milestones reiterated: June 2026 (TTI-109 topline + strategy) and 2H 2026 (TTI-101 HCC topline).